Serum levels of MMP9 and MMP2 in patients with oral squamous cell carcinoma

Asian Pacific Journal of Cancer Prevention

Volumn 16, Issue 4, 2015, Pages 1327-1330

  Lotfi, Alireza ^a   Mohammadi, Ghodrat ^a   Tavassoli, Atena ^b   Mousaviagdas, Mehrnoosh ^a   Chavoshi, Hadi ^b   Saniee, Lale ^b  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Grade; Matrix metalloproteinase 2; Matrix metalloproteinase 9; Squamous cell carcinoma

Indexed keywords

GELATINASE A; GELATINASE B; MMP2 PROTEIN, HUMAN; MMP9 PROTEIN, HUMAN; TUMOR MARKER;

BLOOD; CANCER STAGING; CASE CONTROL STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; LYMPH NODE METASTASIS; MALE; MIDDLE AGED; MOUTH TUMOR; PATHOLOGY; PROGNOSIS; SECONDARY; SQUAMOUS CELL CARCINOMA;

BIOMARKERS, TUMOR; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPHATIC METASTASIS; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; MOUTH NEOPLASMS; NEOPLASM STAGING; PROGNOSIS;

EID: 84926145272     PISSN: 15137368     EISSN: None     Source Type: Journal    
DOI: 10.7314/APJCP.2015.16.4.1327     Document Type: Article

References (33)

1. Abbasi MM, Jahanban-Esfahlan R, Monfaredan A, et al (2014). Oral and IV dosages of doxorubicin-methotrexate loaded-nanoparticles inhibit progression of oral cancer by down-regulation of matrix methaloproteinase 2 expression in vivo. Asian Pac J Cancer Prev, 15, 10705-11.
2. Bedal KB, Grassel S, Oefner PJ, et al (2014). Collagen XVI induces expression of MMP9 via modulation of AP-1 transcription factors and facilitates invasion of oral squamous cell carcinoma. PLoS ONE, 9, 86777.
3. Di Domenico M, Ricciardi C, Fusco A, Pierantoni GM (2011). Anti-VEGF therapy in breast and lung mouse models of cancers. J Biomed Biotechnol, 2011, 947928.
4. de Vicente JC, Fresno MF, Villalain L, et al (2005). Expression and clinical significance of matrix metalloproteinase-2 and matrix metalloproteinase-9 in oral squamous cell carcinoma. Oral Oncol, 41, 283-93.
5. Elahi M, Rakhshan V, Ghasemian NT, Moshref M (2012). Prognostic value of transforming growth factor beta 1 [TGF-β1] and matrix metalloproteinase 9 [MMP-9] in oral squamous cell carcinoma. Biomarkers, 17, 21-7.
6. Erdem NF, Carlson ER, Gerard DA, Ichiki AT (2007). Characterization of 3 oral squamous cell carcinoma cell lines with different invasion and/or metastatic potentials. J Oral Maxillofac Surg, 65, 1725-33.
7. Folgueras AR, Pendas AM, Sanchez LM, Lopez-Otin C (2004). Matrix metalloproteinases in cancer: from new functions to improved inhabitation strategies. Int J Dev Biol, 48, 411-24.
8. Forsyth PA, Wong H, Laing TD, et al (1999). Gelatinase-A (MMP-2), gelatinase-B (MMP-9) and membrane type matrix metalloproteinase-1 (MT1-MMP) are involved in different aspects of the pathophysiology of malignant gliomas. Br J Cancer, 79, 1828-35.
9. Garvin P, Nilsson L, Carstensen J, Jonasson L, Kristenson M (2008). Circulating matrix metalloproteinase-9 is associated with cardiovascular risk factors in a middle-aged normal population. PLoS One, 3, 1774.
10. Hong Q, Jun T, Lei J, Xiling J, Tamamura R (2006). Expression and clinical significance of matrix metalloproteinase-2 and its inhibitor TIMP-2 in oral squamous cell carcinoma. J Hard Tissue Biol, 15, 54-60.
11. Johnson NW, Jayasekara P, Amarasinghe AA (2011). Squamous cell carcinoma and precursor lesions of the oral cavity: epidemiology and aetiology. Periodontology, 57, 19-37.
12. Katayama A, Bandoh N, Kishibe K, et al (2004). Expressions of matrix metalloproteinases in early-stage oral squamous cell carcinoma as predictive indicators for tumor metastases and prognosis. Clin Cancer Res, 10, 634-40.
13. Knapinska A, Fields GB (2012). Chemical biology for understanding matrix metalloproteinase function. Chembiochem, 13, 2002-20.
14. Kondakova IV, Klisho EV, Savenkova OV (2008). Matrix metalloproteinase 2 and 9 as the factor of head and neck tumor metastasis. Biomed Khim, 54, 555-60.
15. Li M, Wang Z, Xing Y, et al (2014). A Multicenter study on expressions of vascular endothelial growth factor, matrix metallopeptidase-9 and tissue inhibitor of metalloproteinase-2 in oral and maxillofacial squamous cell carcinoma. Iran Red Crescent Med J, 16, 13185.
16. Liu G, Li J, Li Z, Chen X (2001). The effects of MMPs and TIMPs on the metastasis of oral squamous cell carcinoma to neck lymph nodes. Hua Xi Kou Qiang Yi Xue Za Zhi, 19, 216-8, 224 (in Chinese).
17. Mäkinen LK, Hayry V, Atula T, et al (2012). Prognostic significance of matrix metalloproteinase-2,-8,-9, and-13 in oral tongue cancer. J Oral Pathol Med, 41, 394-9.
18. Mardani M, Andisheh-Tadbir A, Khademi B, Biparva P, Malekzadeh M (2014). Serum level of matrix metalloproteinase-9 in patients with salivary gland tumor. J Dent Shiraz Univ Med Sci, 15, 199-203.
19. Mohtasham N, Babakoohi S, Shiva A, et al (2013). Immunohistochemical study of p53, Ki-67, MMP-2 and MMP-9 expression at invasive front of squamous cell and verrucous carcinoma in oral cavity. Pathol Res Pract, 209, 110-4.
20. Monteiro-Amado F, Castro-Silva II, Lima CJ, et al (2013). Immunohistochemical evaluation of MMP-2, MMP-9 and CD31/microvascular density in squamous cell carcinomas of the floor of the mouth. Braz Dent J, 24, 3-9.
21. Nikkola J, Vihinen P, Vuoristo MS, et al (2005). High serum levels of matrix metalloproteinase-9 and matrix metalloproteinase-1 are associated with rapid progression in patients with metastatic melanoma. Clin Cancer Res, 11, 5158-66.
22. Pereira AC, Dias do Carmo E, Dias da Silva MA, Blumer Rosa LE (2012). Matrix metalloproteinase gene polymorphisms and oral cancer. J Clin Exp Dent, 4, 297-301.
23. Rosenthal EL, Matrisian LM (2006). Matrix metalloproteinases in head and neck cancers. Head Neck, 10, 639-48.
24. SahebJamee M, Eslami M, AtarbashiMoghadam F, Sarafnejad A (2008). Salivary concentration of INF6, TNFa, IL1a, and IL8 in oral squamous cell carcinoma. Med Oral Patol Oral Cir Bucal, 13, 292-5.
25. Singh RD, Haridas N, Patel JB, et al (2010). Matrix metalloproteinases and their inhibitors: correlation with invasion and metastasis in oral cancer. Indian J Clin Biochem, 25, 250-9.
26. Shuman Moss LA, Jensen-Taubman S, Stetler-Stevenson WG (2012). Matrix metalloproteinases: changing roles in tumor progression and metastasis. Am J Pathol, 181, 1895-9.
27. Tadbir AA, Purshahidi S, Ebrahimi H (2012). Serum level of MMP-3 in patients with oral squamous cell carcinoma-lack association with clinico-pathological features. Asian Pac J Cancer Prev, 13, 4545-8.
28. Vilen ST, Salo T, Sorsa T, Nyberg P (2013). Fluctuating roles of matrix metalloproteinase-9 in oral squamous cell carcinoma. Scientific World Journal, 2013, 920595.
29. Wang G, Wang W, Zhou J, Yang X (2013). Correlation between telomerase activity and matrix metalloproteinases 2 expression in gastric cancer. Cancer Biomark, 13, 21-8.
30. Wu ZS, Wu Q, Yang JH, et al (2008) Prognostic significance of MMP-9 and TIMP-1 serum and tissue expression in breast cancer. Int J Cancer, 122, 2050-6.
31. Yadav L, Puri N, Rastogi V, et al (2014). Matrix metalloproteinases and cancer-roles in threat and therapy. Asian Pac J Cancer Prev, 15, 1085-91.
32. Ylisirnio S, Hoyhtya M, Turpeenniemi-Hujanen T (2000). Serum matrix metalloproteinases-2,-9 and tissue inhibitors of metalloproteinases-1,-2 in lung cancer-TIMP-1 as a prognostic marker. Anticancer Res, 20, 1311-6.
33. Zhang J, Yin L, Wu J, et al (2014). Detection of serum VEGF and MMP-9 levels by Luminex multiplexed assays in patients with breast infiltrative ductal carcinoma. Exp Ther Med, 8, 175-80.